Keymed Biosciences Inc.
HKEX:2162.HK
37.85 (HKD) • At close September 19, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) HKD.
| 2023 Q4 | 2023 Q3 | 2023 Q2 | 2023 Q1 | 2022 Q4 | 2022 Q3 | 2022 Q2 | 2022 Q1 | 2021 Q4 | 2021 Q3 | 2021 Q2 | 2021 Q1 | 2020 Q4 | 2020 Q3 | 2020 Q2 | 2020 Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 13.486 | 13.486 | 163.562 | 163.562 | 0.032 | 0.032 | 50 | 50 | 55.135 | 55.135 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue
| 10.931 | 10.931 | 7.509 | 7.509 | 0.024 | 0.024 | 1.269 | 1.269 | 8.6 | 8.6 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit
| 2.555 | 2.555 | 156.054 | 156.054 | 0.008 | 0.008 | 48.732 | 48.732 | 46.535 | 46.535 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit Ratio
| 0.189 | 0.189 | 0.954 | 0.954 | 0.238 | 0.238 | 0.975 | 0.975 | 0.844 | 0.844 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 173.263 | 173.263 | 124.879 | 124.879 | 171.683 | 171.683 | 82.004 | 82.004 | 83.548 | 83.548 | 95.531 | 95.531 | 43.732 | 43.732 | 19.969 | 19.969 |
| General & Administrative Expenses
| 47.317 | 47.317 | 41.186 | 41.186 | 41.432 | 41.432 | 25.524 | 25.524 | 32.809 | 32.809 | 13.418 | 13.418 | 6.989 | 6.989 | 3.786 | 3.786 |
| Selling & Marketing Expenses
| 0 | 0 | 21.658 | 0 | 27.736 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -0.054 | -0.054 | 0.054 | 0.054 |
| SG&A
| 47.317 | 47.317 | 41.186 | 41.186 | 41.432 | 41.432 | 25.524 | 25.524 | 32.809 | 32.809 | 13.418 | 13.418 | 6.935 | 6.935 | 3.84 | 3.84 |
| Other Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Expenses
| 223.892 | 223.892 | 148.354 | 148.354 | 168.06 | 168.06 | 55.437 | 55.437 | 177.662 | 177.662 | 1,813.129 | 1,813.129 | 387.428 | 387.428 | 17.583 | 17.583 |
| Operating Income
| -218.514 | -218.514 | -10.202 | -10.202 | -213.449 | -213.449 | -58.797 | -58.797 | -71.112 | -71.112 | -109.138 | -109.138 | -50.682 | -50.682 | -23.808 | -23.808 |
| Operating Income Ratio
| -16.204 | -16.204 | -0.062 | -0.062 | -6,776.159 | -6,776.159 | -1.176 | -1.176 | -1.29 | -1.29 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| 16.347 | 16.347 | 34.274 | 34.274 | 60.389 | 60.389 | 60.059 | 60.059 | -59.989 | -59.989 | -1,706.078 | -1,706.078 | -341 | -341 | 6.065 | 6.065 |
| Income Before Tax
| -202.167 | -202.167 | 24.073 | 24.073 | -153.061 | -153.061 | 1.262 | 1.262 | -131.101 | -131.101 | -1,815.216 | -1,815.216 | -391.681 | -391.681 | -17.743 | -17.743 |
| Income Before Tax Ratio
| -14.991 | -14.991 | 0.147 | 0.147 | -4,859.063 | -4,859.063 | 0.025 | 0.025 | -2.378 | -2.378 | 0 | 0 | 0 | 0 | 0 | 0 |
| Income Tax Expense
| 0.799 | 0.799 | 3.704 | 0.589 | 9.367 | 3.724 | -1.465 | -1.465 | -1.696 | -1.696 | -0.966 | -0.966 | -0.133 | -0.133 | 0 | 0 |
| Net Income
| -203.162 | -203.162 | 23.484 | 23.484 | -156.785 | -156.785 | 2.727 | 2.727 | -129.405 | -129.405 | -1,814.25 | -1,814.25 | -391.549 | -391.549 | -17.743 | -17.743 |
| Net Income Ratio
| -15.065 | -15.065 | 0.144 | 0.144 | -4,977.286 | -4,977.286 | 0.055 | 0.055 | -2.347 | -2.347 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS
| -0.78 | -0.78 | 0.09 | 0.09 | -0.6 | -0.6 | 0.01 | 0.01 | -0.51 | -0.51 | -27.04 | -27.04 | -5.84 | -5.84 | -0.26 | -0.26 |
| EPS Diluted
| -0.78 | -0.78 | 0.088 | 0.088 | -0.6 | -0.6 | 0.01 | 0.01 | -0.51 | -0.51 | -27.04 | -27.04 | -5.84 | -5.84 | -0.26 | -0.26 |
| EBITDA
| -201.948 | -201.948 | -0.953 | -0.953 | -206.678 | -206.678 | -54.431 | -54.431 | -68.392 | -68.392 | -105.457 | -105.457 | -46.7 | -46.7 | -20.843 | -20.843 |
| EBITDA Ratio
| -14.975 | -14.975 | -0.006 | -0.006 | -6,561.19 | -6,561.19 | -1.089 | -1.089 | -1.24 | -1.24 | 0 | 0 | 0 | 0 | 0 | 0 |